T helper 17 cell

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, Conference, Pneumonia, CRAC, Disease, Incidence, GFR, AKI, Patient, Physiology, COVID-19, Renal artery, Biomarker, Hemofiltration, T helper 17 cell, Mortality, Indiana University, Cell biology, Glomerular filtration rate, Respiratory failure, Doctor of Philosophy, Acute kidney injury, Ischemia, Kidney, Poster, Stage 2, Blood, Animal, Hospice and palliative medicine, Pharmaceutical industry

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)

Retrieved on: 
Tuesday, October 17, 2023
STAT3, PASI, TYK2, Haematopoiesis, Biology, Crohn's disease, Parasitism, SRC, Inflammation, JAK, Bacteria, SH2, T helper 17 cell, Psoriasis, Disease, Cancer, Ulcerative colitis, Rheumatoid arthritis, Virus, SAN, Multiple sclerosis, Phenotype, Doctor of Pharmacy, Pharmaceutical industry, Vaccine

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that in a presentation given today titled “Drugging the Undruggable,” Recludix’s senior vice president of biology, Paul Smith, Ph.D., discussed the first application of the company’s platform capabilities to target the Src Homology 2 (SH2) domain, as well as reviewed preclinical data on an early STAT3 inhibitor that was internally discovered through the platform. The presentation is available on the company’s website under the section titled “Events.”

Key Points: 
  • “In this presentation, we highlight data from one of our earlier STAT3 discovery compounds showing its highly selective STAT3 inhibition with demonstrated potency in biochemical and cellular assays.
  • We have continued to refine our lead STAT3 inhibitors and are in the final stages of confirming a STAT3 development candidate to move into clinical testing.
  • Data demonstrate that targeting STAT3 spares interferon-driven anti-viral gene transcription and avoids STAT5 signaling, which is important for hematologic homeostasis and is differentiated from JAK/TYK2 inhibition.
  • Activity for STAT3 was found to be dose-dependent in both prophylactic and therapeutic preclinical models.

The Inner Circle Acknowledges, James G. Krueger MD, Ph.D., as a Pinnacle Life Member for his contributions to the field of Dermatology

Retrieved on: 
Thursday, August 31, 2023
COPSS Distinguished Achievement Award and Lectureship, Tissue, Bachelor, ABD, Therapy, Weill Cornell Medicine, Doctor of Philosophy, Internal medicine, Education, Rockefeller University, American Board of Dermatology, Head, Pharmacogenomics, Research fellow, Skin, Psoriasis, T helper 17 cell, Medicine, Research, Gene expression, Inflammation, Princeton University, Rheumatoid arthritis, Science, Trial of the century, Inflammatory bowel disease, Inner circle, American Board of Commissioners for Foreign Missions, Cell biology, Patient, Hidradenitis suppurativa, Physician, Immune system, Knowledge, Diagnosis, Innovation, Laboratory, Nursing, Vaccine, Pharmaceutical industry, Dermatology, Virology

NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Member for his contributions to the field of Dermatology.

Key Points: 
  • NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Member for his contributions to the field of Dermatology.
  • Dr. Krueger's prestigious higher education began at Princeton University where he earned a Bachelor's degree.
  • Dr. Krueger's current post is at Rockefeller University Hospital where he serves as Head of the Laboratory for Investigative Dermatology and is also a professor in Clinical Investigation and Dermatology.
  • The doctor asserts that dermatology is the branch of medicine dealing with the skin, which is the largest organ of the body.

The Inner Circle Acknowledges, James G. Krueger MD, Ph.D., as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist

Retrieved on: 
Friday, May 5, 2023
COPSS Distinguished Achievement Award and Lectureship, Tissue, Bachelor, ABD, Therapy, Weill Cornell Medicine, Doctor of Philosophy, Education, Internal medicine, Rockefeller University, Head, Professional, Pharmacogenomics, Research fellow, Skin, Psoriasis, T helper 17 cell, Medicine, Research, Gene expression, Multimedia, Inflammation, Princeton University, Rheumatoid arthritis, Science, Trial of the century, Inflammatory bowel disease, Inner circle, American Board of Commissioners for Foreign Missions, Cell biology, Patient, Hidradenitis suppurativa, Physician, American Board of Dermatology, Immune system, Knowledge, Diagnosis, Innovation, Laboratory, Vaccine, Pharmaceutical industry, Dermatology, Virology

NEW YORK, May 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist.

Key Points: 
  • NEW YORK, May 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist.
  • Dr. Krueger pursued higher education at Princeton University where he earned a Bachelor's degree from Princeton University.
  • He received a medical degree from Cornell University Medical College and completed an internship in internal medicine and a residency in dermatology.
  • According to Dr. Krueger, the laboratory at The Rockefeller University Hospital conducts clinical research on patients with psoriasis vulgaris.

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 1, 2023
G&A, Sale, Patient, B cell, GPP, RA, SAN, Lilly, BTLA, PD-1, Rheumatoid arthritis, Therapy, IGA, Research, AD, Lung cancer, R, T helper cell, Atopic dermatitis, Investment, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, TH1, T helper 17 cell

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2022 and provided business updates.

Key Points: 
  • SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2022 and provided business updates.
  • “2022 was a significant year of transition for AnaptysBio as we refocused the company on broadly advancing our portfolio of best-in-class immune cell modulators.
  • Cash, cash equivalents and investments totaled $584.2 million as of December 31, 2022, compared to $615.2 million as of December 31, 2021, for a decrease of $31.0 million.
  • We also had an additional sale of future royalties in 2022 compared to period in 2021.

ASN002 (Gusacitinib) Emerging Drug Insight and Market 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Health, Pharmaceutical, Janus, Clinical trial, HE, JAK, JAK3, News, SYK, B cell, JAK1, Research, United Kingdom, EU4, T helper 17 cell, Keratinocyte, CHE, T helper cell, Neutrophil, Book, Pancreatic serous cystadenoma, Macrophage, JAK2, TYK2, Cytokine, Lymphoma, Epithelium, SWOT, Fine chemical, Pharmaceutical industry, Vaccine, Hand eczema

The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of future market assessments inclusive of the ASN002 (Gusacitinib) market forecast, analysis for Hand Eczema in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
  • Other emerging products for Hand Eczema (HE) are expected to give tough market competition to ASN002 (Gusacitinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What is the clinical trial status of the study related to ASN002 (Gusacitinib) in Hand Eczema (HE) and study completion date?